Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture.
The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.
Gabel
D
D
Department of Chemistry, University of Bremen, Federal Republic of Germany.
Preusse
D
D
Haritz
D
D
Grochulla
F
F
Haselsberger
K
K
Fankhauser
H
H
Ceberg
C
C
Peters
H D
HD
Klotz
U
U
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001894:Borohydrides / Q000493:pharmacokinetics*; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000532:radiotherapy*; D005260:Female; D005910:Glioma / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
D001894:Borohydrides